Connaissances Accueil Santé humaine Connaissances All Avis Exposés Science populaire Entretiens Filtrer Therapeutic areas COVID-19 Santé digestive Apply Accueil Santé humaine Connaissances Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months Accueil Santé humaine Connaissances Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial Accueil Santé humaine Connaissances Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2 Accueil Santé humaine Connaissances RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine? Accueil Santé humaine Connaissances RBDCOV: The project’s origins and future endeavours Accueil Santé humaine Connaissances Humoral immune response against XBB.1.5 and BQ.1.1 SARS-CoV-2 variants of a fourth dose of PHH-1V vaccine in adult subjects Accueil Santé humaine Connaissances Reactogenicity of third and fourth booster doses of HIPRA PHH-1V, a bivalent recombinant protein vaccine against SARS-CoV-2 Accueil Santé humaine Connaissances Humoral immune response against SARS-CoV-2 variants of PHH-1V booster vaccine in subjects previously vaccinated with a mRNA vaccine Accueil Santé humaine Connaissances One-year humoral response of PHH-1V booster vaccine in subjects previously vaccinated against COVID-19 with a mRNA vaccine Charger plus
